Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Arovella Therapeutics Limited ( (AU:ALA) ) has shared an announcement.
Arovella Therapeutics presented new pre-clinical data on its CLDN18.2-targeting CAR-iNKT cell therapy at the American Association for Cancer Research annual meeting in San Diego. The poster detailed how CLDN18.2 CAR-iNKT cells effectively killed CLDN18.2-positive pancreatic and gastric cancer cells in vitro, underscoring the potential of the company’s IL-12-TM armoured, allogeneic iNKT platform to expand its presence in solid tumour immunotherapy and reinforce its profile among cancer researchers and industry stakeholders.
Management highlighted the strong performance of the CLDN18.2 construct and the added benefit from incorporating IL-12-TM, signalling continued investment in generating further data to support future development. By showcasing this program at a major global cancer research forum, Arovella gains scientific visibility and validation that could help attract partners, talent and capital as it broadens its pipeline beyond blood cancers into difficult-to-treat solid tumours.
More about Arovella Therapeutics Limited
Arovella Therapeutics is an Australian biotechnology company developing an invariant Natural Killer T (iNKT) cell therapy platform to treat blood cancers and solid tumours. Its lead product, ALA-101, is an allogeneic CAR19-iNKT cell therapy targeting CD19-positive cancers, with an accepted IND from the U.S. FDA, and it is also advancing CLDN18.2-targeting and IL-12-TM armouring technologies for solid tumours.
Average Trading Volume: 1,054,821
Technical Sentiment Signal: Sell
Current Market Cap: A$104M
For a thorough assessment of ALA stock, go to TipRanks’ Stock Analysis page.